Logo
Login
$RVMD
$183.90 -$3.09 (1.65%) Close

Company Executives

$RVMD Management Team

Dr. Mark Goldsmith

Chairman of the Board

President

Chief Executive Officer

Age 63
Compensation $10.08M USD
Sex Male

Dr. Steve Kelsey

President - Research and Development

Age 64
Compensation $5.950M USD
Sex Male

Ms. Margaret Horn

Chief Operating Officer

Age 62
Compensation $4.884M USD
Sex Female

Ms. Xiaolin Wang

Executive Vice President - Development

Age 55
Compensation $3.054M USD
Sex Female

Mr. Jeff Cislini

Senior Vice President

General Counsel

Secretary

Age 50
Compensation -
Sex Male

Dr. Wei Lin

Chief Medical Officer

Age 56
Compensation -
Sex Male

Dr. Alan Sandler

Chief Development Officer

Age 68
Compensation -
Sex Male

Mr. Jack Anders

Chief Financial Officer

Age 48
Compensation $3.293M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 27, 2026
Directors
9
serving now
Independent
0 of 1
stated in the proxy; 8 not stated
Average tenure
6.8 years
from year joined
CEO also chairs the board
Yes
Mark A. Goldsmith, M.D., Ph.D.
Director Age On board Independent Committees Other public boards 2025 pay Source
Alexis Borisy
54 2014
12 years
 Not stated None stated Relay Therapeutics, Inc. $481,225
Mark A. Goldsmith, M.D., Ph.D.
Board chair, CEO
 64 2014
12 years
 Not independent None stated None stated Paid as CEO
Elizabeth McKee Anderson
68 2015
11 years
 Not stated
Compensation Committee · Chair Commercialization Committee
GSK plc (NYSE: GSK) $461,620
Flavia Borellini, Ph.D.
66 2021
5 years
 Not stated
Research and Development Committee · Chair
None stated $461,225
Lorence Kim, M.D.
52 2022
4 years
 Not stated
Nominating and Corporate Governance Committee · Chair
Cencora, Inc. (NYSE: COR) $468,329
Frank K. Clyburn, Jr.
61 2024
2 years
 Not stated
Commercialization Committee · Chair
Kailera Therapeutics, Inc. (Nasdaq: KLRA) $419,497
Sandra J. Horning, M.D.
77 2023
3 years
 Not stated
Research and Development Committee
Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) $445,829
Sushil Patel, Ph.D.
55 2022
4 years
 Not stated None stated None stated $455,829
Thilo Schroeder, Ph.D.
45 2018
8 years
 Not stated None stated None stated Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 27, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans